Medical Devices Group

  • Community
  • Webinars
  • Jobs
  • Events
  • Contact
  • Go Premium
« Back to Previous Page
like comment  share
Joe Hage
🔥 Find me at MedicalDevicesGroup.net 🔥
February 2012
Arterial vs venous stent?
Veniti Medical first to distinguish them.
5 min reading time

Sean Morris Veniti 175I don’t mind admitting it. I thought a stent was a stent.

#MedDevice guest Sean Morris, the CEO of Veniti Medical, pioneers in the venous disease space, taught me something new. Today, there is no such thing as a dedicated stent for veins!

Well, not yet. That’s where Veniti comes in.

Sean Morris: Thanks for having me, Joe. Veniti Medical is a start up company with multiple products for chronic disease treatment. We have been around since January of 2010 and are unique in that we are the first company dedicated to this space.

Joe Hage: You are two years old now. Did you found the company, Sean? How many are you now?

Sean Morris: I, along with some thought leaders in the venous space, started the company. Veniti now has 15 employees having recently brought on a high caliber COO. I am very proud of the team we’ve assembled.

You say you are the first in the space. Was no one serving this market or was no one focused exclusively on it? We are the first company that has emerged with a pure focus on venous disease and with multiple products. You say you are the first in the space. Was no one serving this market or was no one focused exclusively on it? We are the first company that has emerged with a pure focus on venous disease and with multiple products.

Joe Hage: Please educate me. Who else is in the space and how big is the market globally?

Sean Morris: There is a huge interest in this $5-billion global market.

Chronic venous disease can be deadly. Serious conditions such as deep venous thrombosis and pulmonary embolisms are dangerous effects of venous disease. 40 percent of adults are estimated to have venous disease. That’s 25 percent of the total population.

Covidien has been very active having purchased VNUS medical, Bacchus Vascular and ev3 in the past three years. Beyond this, every company they compete with (Boston Scientific, Bard, AngioDynamics, Maquet, Abbott; others) are monitoring this area.

Joe Hage: According to your website, your first three products are still in development: an ablation device, a vena cava filter, and a venous stent.

Are these products already offered by your competitors? If so, why should vascular surgeons look at you? Great question Joe. All of our technologies meet an unmet need, are disruptive and "do more" than what is currently available.

Our ablation system has been designed to provide comprehensive therapy to all types of veins, beyond what is currently available.

Our vena cava filter allows for active anchoring which serves to keep the filter centered and migration free.

Our venous stent is the first of its kind and built from the start to be a venous stent. We also have a unique delivery system.

What does that mean, "built from the start to be a venous stent"? Physicians have been placing "arterial stents" in the venous system for decades. A vein is not an artery and vice versa. A vein heals and responds differently than its arterial counterpart. Veins are more rugged, are larger and are more complex.

Joe Hage: Sean, you are saying, the venous stents on the market today are adaptations of competitors’ arterial stents?

Sean Morris: Today, an FDA approved venous stent does not exist.

We are bringing the first venous stent to market. It took us an entire year to figure out what our 1st generation stent would need to look like before we made our 1st prototype. Veins are complex and require a complex system for optimal results.

Joe Hage: How protect-able is your technology? How easily can your competitors reverse engineer it and compete against you?

Sean Morris: I believe this would be difficult. Our stent is made of Nitinol and tweaked in a very specific way to optimize clinical results. Given our extensive comprehensive research, we feel we have the right recipe and the recipe is secret.

Joe Hage: Before we continue, Sean, what is your background? Engineering? Sales? How and why did you break away to start your own thing?

Sean Morris: I have an extensive background in sales, marketing, strategy and operations. I started Veniti because I have a passion for this space and love the idea of building something and providing jobs to people. I learned from some of the best at my former employer AngioDynamics and it was there were I developed my interest in venous disease therapies.

Did you approach $ANGO with this idea first? What did they say? I know the folks there had heard from me, and others about these ideas and concepts. I became impatient and did it myself. Sounds like a tale of caution to established players unable to capitalize on their team's ideas!

Sean Morris: I think you are right, Joe. There are great minds and passionate people in every organization. I know I’m not the 1st to do this.

Joe Hage: What is the timeline for clearance? Are you targeting the US first? We’ve been debating the merits of FDA versus CE in the Medical Devices Group.

Sean Morris: There is a global need for our technologies and we intend to work with the FDA and our colleagues overseas to gain approvals. Our product launches will be staged. We expect our ablation system to be ready this summer, followed by our stent, and then filter.

Joe Hage: Without a predicate device, this must be costing you a friggin’ fortune!

Sean Morris: Bringing a medical device to market is expensive and we plan for the worst and hope for the best. We have excellent VC investors that are dedicated to our cause and a strong board. It’s up to us to execute and I am confident the team we have in place is up for the challenge. The key is to stay focused, spend wisely and mitigate risks.

Joe Hage: Will you be going through distribution? Hiring a sales force? Working with a manufacturer’s rep?

Sean Morris: I am very biased towards going direct. With our mission, we need maximum efficiency and direct is the only way to get that.

Joe Hage: Excellent. Last question today, Sean, and thanks so much for joining us.

What would you like to tell the 90,000 members of the Medical Devices Group and how might they help you?

Sean Morris: Thanks Joe! The best way to answer that is with a real life experience. I spent last week the American Venous Forum meeting in Orlando, FL. Every physician I spoke with discussed how much there was still to learn about this disease state.

Physicians said they understand they don’t have the right devices for venous disease. They “don’t know what they don’t know” and have “decades of research ahead of us.”

I’d conclude by telling the Medical Devices Group to learn more about the differences between aertial and venous disease states and, when our products come to market, to learn more about the possibilities with us.

Marked as spam
Posted by Joe Hage
Asked on February 17, 2012 9:15 pm
158 views
  • Follow
  • Unfollow
  • Report spam
like comment  share

Meet your next client here. Join our medical devices group community.

« Back to Previous Page
Ask a Question
Leave a Comment

We still use LinkedIn to access our site because it’s the only way to “pull in” your LinkedIn photo, name, and hyperlink to your profile page, all vital in building your professional network. When you log in using LinkedIn, you are giving LinkedIn your password, not me. I never see nor store your LinkedIn credentials.

Stay connected with us.

By signing up you are agreeing to our Privacy Policy.

Categories

  • Capital/Investment
    • Business Model
    • Funding
  • Careers
  • Design/Devel
    • Design
    • Development
    • Human Factors
    • Labeling
    • Material Selection
    • R&D
    • Trials and Post-Market
  • Featured
  • Industry
    • Announcements
    • Device Tax
    • Hospital and Health Care
    • Innovation
    • Medtech
  • LinkedIn, etc.
  • Markets
    • Africa
    • Americas
    • Asia
    • Australia
    • Europe
  • Regulating
    • CE Marking
    • EU
    • FDA
    • FDA/EU etc.
    • Notified Bodies
    • Quality
    • Regulatory
  • Selling
    • Distribution
    • Intellectual Property
    • Marketing/Sales
    • Reimbursement
  • Worth bookmarking!
Feature your job here.
logo

Companion to LinkedIn's 350,000 member community

  • Contact
  • Medical Device Marketing
  • In Memoriam
  • Medical Device Conference

The Medical Devices Group   |   Copyright © 2025 Terms, Conditions & Privacy

Medical Devices Group
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.